• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Exelixis Inc (NQ: EXEL )

    36.10 -0.09 (-0.25%)
    Streaming Delayed Price Updated: 12:49 PM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Exelixis Inc

    < Previous 1 2 3 4 5 Next >
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
    From Exelixis, Inc.
    Via Business Wire
    Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
    From Exelixis, Inc.
    Via Business Wire
    3 Stocks to Buy for a Soft Landing, If There Is One
    Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes 
    Via MarketBeat
    Topics Economy
    Exposures Economy Interest Rates
    Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
    From Exelixis, Inc.
    Via Business Wire
    Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
    From FN Media Group LLC
    Via GlobeNewswire
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
    From Exelixis, Inc.
    Via Business Wire
    Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
    From Bristol Myers Squibb
    Via Business Wire
    European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
    From Exelixis, Inc.
    Via Business Wire
    Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
    From Exelixis, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.